On November 27, 2024 Bio-Techne Corporation (NASDAQ: TECH) reported that Kim Kelderman, President and Chief Executive Officer, will present at the Citi 2024 Global Healthcare Conference on Wednesday, December 4, 2024, at 3:15 p.m. EST (Press release, Bio-Techne, NOV 27, 2024, View Source [SID1234648679]). A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne’s Investor Relations website at View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On November 27, 2024 Rakovina Therapeutics Inc. (TSX-V: RKV, the "Company" or "Rakovina Therapeutics"), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, reported a non-brokered private placement offering (the "Offering") of up to $1.25 million (Press release, Rakovina Therapeutics, NOV 27, 2024, View Source;utm_medium=rss&utm_campaign=rakovina-therapeutics-announces-private-placement-offering [SID1234648695]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company has received initial commitments totaling over $800,000 from strategic investors in connection with the Offering.

The Offering is structured as units priced at $0.06 each, with each unit consisting of one common share and one warrant to purchase a common share. Each warrant entitles the holder to purchase one additional common share at a price of $0.10 per share, exercisable for a period of 24 months. Rakovina retains the right to accelerate the warrant exercise period if the 20-day volume-weighted average price of its shares exceeds $0.30.

The Company plans to use the proceeds to continue the discovery and advancement of novel cancer treatments by leveraging collaborations with two proprietary Artificial Intelligence (AI) platforms: the Deep Docking AI platform and the Variational AI Enki Platform. The Company also plans to continue the development of its kt-3000 series through collaborations and partnerships with biotech and pharma companies.

"We are deeply grateful to our investors—both long-standing and new—whose confidence reinforces the promise of our development efforts," said Jeffrey Bacha, Executive Chairman of Rakovina Therapeutics. "Our recent data demonstrates that the Deep Docking AI platform has delivered on its objective, generating a focused shortlist of potential best-in-class PARP-1 inhibitor candidates capable of crossing the blood-brain barrier. The next critical step is validating these promising candidates using our wet-lab infrastructure at the University of British Columbia while advancing work on our next target. This financing provides the additional resources necessary to achieve these goals."

The Units will be sold on a non-brokered "private placement" basis by qualified finders in accordance with applicable Canadian securities laws and under applicable exemptions from prospectus and registration requirements, and the securities will be subject to resale restrictions for a period of four months plus one day from the date of issue.

On November 26, 2024 Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, reported that members of the Aclaris management team will participate in a fireside chat during the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 1:00 PM ET in New York, New York (Press release, Aclaris Therapeutics, NOV 26, 2024, View Source [SID1234648647]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the fireside chat may be accessed through the "Events" page of the "Investors" section of Aclaris’ website, www.aclaristx.com. The webcast will be archived for at least 30 days on the Aclaris website.

On November 26, 2024 Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, reported participation in three upcoming investor conferences (Press release, Ultragenyx Pharmaceutical, NOV 26, 2024, View Source [SID1234648664]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi’s 2024 Global Healthcare Conference (Miami, FL)

Tuesday, December 3, 2024, Emil Kakkis, M.D., Ph.D., CEO and President and Howard Horn, Chief Financial Officer, will participate in a fireside chat and host 1×1 meetings.

7th Annual Evercore ISI HealthCONx Conference (Coral Gables, FL)

Wednesday, December 4, 2024, Emil Kakkis and Howard Horn will participate in a fireside chat and host 1×1 meetings.
Piper Sandler’s 36th Annual Healthcare Conference (New York, NY)

Thursday, December 5, 2024, Eric Crombez, M.D., Chief Medical Officer and Howard Horn will participate in a fireside chat and host 1×1 meetings.
The live and archived webcast of the fireside chats will be accessible from the company’s website at View Source

On November 26, 2024 Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, reported that members of management will present at two investor conferences being webcast in December (Press release, Aligos Therapeutics, NOV 26, 2024, View Source [SID1234648648]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Piper Sandler 36th Annual Healthcare Conference
Fireside Chat at 11:00am ET/8:00am PT on December 3, 2024
Evercore ISI 7th Annual HealthCONx Conference
Fireside Chat at 4:15pm ET/1:15pm PT on December 3, 2024

In addition to the presentations, management will participate in one-on-one meetings. A live webcast of each event will be accessible by visiting the "Investors" page of Aligos’ website at www.aligos.com. A replay of the webcasts will be available following the presentation for at least 30 days.